- Zydus Lifesciences’ net income for the first quarter was 14.7 billion rupees, which is a 3.5% increase from the previous year and exceeded estimates of 13.32 billion rupees.
- The company’s revenue reached 65.7 billion rupees, marking a 5.8% rise year over year, surpassing the estimated 64.78 billion rupees.
- Total costs increased by 10% compared to the previous year, totaling 48.1 billion rupees, higher than the estimated 45.71 billion rupees.
- Other income significantly increased to 1.55 billion rupees from 632 million rupees year over year.
- Analysts’ current evaluations include 14 buy ratings, 13 hold ratings, and 7 sell ratings for Zydus Lifesciences.
Zydus Lifesciences Ltd on Smartkarma
Analyst coverage of Zydus Lifesciences Ltd on Smartkarma reveals insights from Nimish Maheshwari, who provided a bearish perspective in the report titled ‘Business Breakdown: Zydus Lifesciences ~ Bet on R&D and New Launches to Fill the Revenue Gap.’ Zydus Lifesciences Ltd operates as a global healthcare company, focusing on generic drugs, biosimilars, and innovative therapies to counter the potential slowdown risk associated with Revlimid. Despite this challenge, Zydus aims to leverage its robust pipeline of new product launches and research and development efforts to mitigate the impact. The company has demonstrated a consistent outperformance in secondary sales compared to market growth, particularly in chronic and specialty products.
A look at Zydus Lifesciences Ltd Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 4 | |
| Growth | 4 | |
| Resilience | 5 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 4.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Looking at the long-term outlook for Zydus Lifesciences Ltd, the company seems to be in a good position based on the Smartkarma Smart Scores. With a solid Value score of 3, indicating a reasonable valuation, investors may find Zydus Lifesciences to be an attractive investment option. Furthermore, the company scores well in areas of Dividend, Growth, and Momentum, with scores of 4 in each category. This suggests that Zydus Lifesciences is focused on rewarding shareholders, showing potential for growth, and exhibiting positive market momentum.
Additionally, Zydus Lifesciences Ltd demonstrates exceptional Resilience with a score of 5. This indicates that the company has the ability to withstand economic uncertainties and market volatility, making it a stable and reliable choice for investors looking for long-term sustainability. Overall, Zydus Lifesciences Ltd appears to offer a promising investment opportunity, supported by a strong performance across key factors outlined by the Smartkarma Smart Scores.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
